Mylan Laboratories Limited
34 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
5
Ending by 2030
Dec 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 6, 2027The maintenance fee for Hot melt granulation formulations of poorly water-soluble active agents (US 10,369,108) comes due Feb 6, 2027. Unpaid by Aug 6, 2027, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 18, 2026
- 3 terms have ended since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,446,227 | Process for Preparation of 5H-DIBENZO[A,D] Cycloheptene Derivatives In force · High confidence | In force | High confidence | |
| US 8,367,080 | Pharmaceutical formulation for use in HIV therapy In force · From the USPTO record | In force | From the USPTO record | |
| US 8,049,009 | Process for the preparation of Tenofovir In force · From the USPTO record | In force | From the USPTO record | |
| US 8,247,568 | Process for the preparation of pure rabeprazole In force · From the USPTO record | In force | From the USPTO record | |
| US 8,974,824 | Lanthanum Composition In force · High confidence | In force | High confidence | |
| US 10,369,108 | Hot melt granulation formulations of poorly water-soluble active agents In force · From the USPTO record | In force | From the USPTO record | |
| US 10,800,777 | Polymorphic forms of VENCLEXTA In force · From the USPTO record | In force | From the USPTO record | |
| US 10,221,184 | Novel polymorphs of ponatinib hydrochloride In force · High confidence | In force | High confidence | |
| US 12,648,912 | Pharmaceutical Composition Comprising Meloxicam In force · High confidence | In force | High confidence | |
| US 12,398,100 | Methods and intermediates for preparing hydrochloride salt of 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 12: 34 patents in force now held by others · 23 lapsed for an unpaid fee · 4 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 2 abandoned · 26 no status recorded